Paysign's Q4 2024 performance featured double-digit revenue growth driven by significant expansion in the patient affordability segment, while plasma revenue softened due to market normalization. The company posted $1.37 million in net income and ended the quarter with $10.77 million in cash.
Total Q4 2024 revenue was $15.61 million, up 14% year-over-year.
Net income for the quarter reached $1.37 million with diluted EPS of $0.02.
Patient affordability revenue surged by 156.5% to $4.31 million.
Plasma revenue declined 6.2% to $10.80 million due to normalized inventory levels.
Paysign anticipates continued growth in 2025, driven by patient affordability revenue, while plasma revenue is expected to moderate. Full-year revenue is projected between $68.5 million and $70.0 million, with pharma revenue doubling year-over-year.
Visualization of income flow from segment revenue to net income